.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

VIGAMOX Drug Profile

« Back to Dashboard
Vigamox is a drug marketed by Alcon Pharms Ltd and is included in one NDA. It is available from five suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in VIGAMOX is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. There are three tentative approvals for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.

Summary for Tradename: VIGAMOX

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list5
Drug Prices: :see details

Pharmacology for Tradename: VIGAMOX

Ingredient-typeQuinolones
Drug ClassQuinolone Antimicrobial

Clinical Trials for: VIGAMOX

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Pharms Ltd
VIGAMOX
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC021598-001Apr 15, 2003RXYes6,716,830*PEDMar 29, 2020Y
Alcon Pharms Ltd
VIGAMOX
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC021598-001Apr 15, 2003RXYes7,671,070*PEDMar 29, 2020Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VIGAMOX

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alcon Pharms Ltd
VIGAMOX
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC021598-001Apr 15, 20034,990,517*PED<disabled>
Alcon Pharms Ltd
VIGAMOX
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC021598-001Apr 15, 20035,607,942*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VIGAMOX

Drugname Dosage Strength RLD Submissiondate
moxifloxacin hydrochlorideOphthalmic0.50%Vigamox12/22/2005
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc